NurExone Biologic Inc. Stock Toronto S.E.
Equities
ENER
CA29278Q1063
Biotechnology & Medical Research
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 24.11M 32.94M |
---|---|---|---|---|---|
Net income 2024 * | -4M -5.46M | Net income 2025 * | -4M -5.46M | EV / Sales 2024 * | - |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-3.99
x | P/E ratio 2025 * |
-3.99
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 92.17% |
Managers | Title | Age | Since |
---|---|---|---|
Lior Shaltiel
CEO | Chief Executive Officer | - | 21-03-31 |
Eran Ovadya
DFI | Director of Finance/CFO | - | 22-06-14 |
Members of the board | Title | Age | Since |
---|---|---|---|
Jay Richardson
BRD | Director/Board Member | 78 | 22-01-02 |
Gadi Riesenfeld
BRD | Director/Board Member | 79 | 23-07-05 |
Yoram Drucker
CHM | Chairman | 59 | 19-12-31 |
1st Jan change | Capi. | |
---|---|---|
+54.05% | 58.71B | |
-2.02% | 41.31B | |
+37.49% | 39.2B | |
-10.22% | 27.4B | |
+13.42% | 26.55B | |
-21.60% | 18.98B | |
+2.89% | 12.51B | |
+22.40% | 11.94B | |
+27.49% | 12.08B |